- Home
- KLTR vs IPHA Comparison
KLTR vs IPHA Comparison
Compare KLTR & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLTR | IPHA |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 232.7M | 174.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | KLTR | IPHA |
|---|---|---|
| Price | $1.63 | $1.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $3.50 | ★ $5.00 |
| AVG Volume (30 Days) | ★ 399.4K | 21.7K |
| Earning Date | 11-10-2025 | 09-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $180,921,000.00 | $14,839,695.00 |
| Revenue This Year | $3.10 | $22.29 |
| Revenue Next Year | $1.24 | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.88 | N/A |
| 52 Week Low | $1.36 | $1.47 |
| 52 Week High | $2.82 | $3.51 |
Technical Indicators
Market Signals| Indicator | KLTR | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 42.81 |
| Support Level | $1.54 | $1.85 |
| Resistance Level | $1.80 | $1.91 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 54.32 | 11.63 |
Price Performance
Historical ComparisonAbout KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.